Zimmer Biomet (ZBH) will announce its quarterly results on Thursday

Zimmer Biomet (NYSE:ZBH – Get Free Report) will announce its earnings data before the market opens on Thursday, May 2. Analysts expect Zimmer Biomet to post earnings of $1.88 per share for the quarter. Zimmer Biomet has set its FY 24 guidance at $8.00-8.15 EPS and its FY 2024 guidance at 8,000-8,150 EPS. Investors interested in registering for the company’s conference call can do so via this link.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last reported its earnings results on Thursday, February 8. The medical device supplier reported $2.20 earnings per share for the quarter, beating analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. In the same quarter last year, the company posted earnings per share of $1.88. Zimmer Biomet’s quarterly revenue increased 6.3% compared to the same quarter last year. On average, analysts expect Zimmer Biomet to post earnings per share of $8 for the current fiscal year and earnings of $9 for the next fiscal year.

Zimmer Biomet Price-performance

Shares of Zimmer Biomet opened at $121.17 on Thursday. Zimmer Biomet has a one-year low of $102.00 and a one-year high of $149.25. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. The company has a fifty day moving average of $126.18 and a two hundred day moving average of $119.46. The company has a market cap of $24.90 billion, a price-to-earnings ratio of 24.78, a price-to-earnings-growth ratio of 2.22 and a beta of 1.01.

Dividend announcement from Zimmer Biomet

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30. A dividend of $0.24 will be paid to shareholders of record on Friday, March 29. This represents a dividend of $0.96 annually and a yield of 0.79%. The ex-dividend date is Wednesday, March 27. Zimmer Biomet’s dividend payout ratio (DPR) currently stands at 19.63%.

Insider buying and selling at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a filing with the SEC, which can be accessed via this hyperlink. Currently, 0.70% of the shares are owned by corporate insiders.

Wall Street analysts weigh in

A number of equity research analysts have commented on ZBH stock. JPMorgan Chase & Co. raised their target price on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, February 9th. StockNews.com downgraded Zimmer Biomet from a “strong buy” rating to a “buy” rating in a research note on Monday, February 19th. TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8. Royal Bank of Canada reaffirmed an “outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 9th. Finally, Truist Financial raised their price objective on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $139.39.

Check out our latest stock report on ZBH

Zimmer Biomet Company Profile

(Get a free report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates worldwide as a medical technology company. The company designs, manufactures and sells orthopedic reconstructive products, such as knee and hip products; SET products, including sports medicine, biological products, foot and ankle products, extremities and trauma products; craniomaxillofacial and thoracic products which include products for facial and cranial reconstruction, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma or for thoracic deformities.

Featured Stories

Get daily news and reviews for Zimmer Biomet – Enter your email address below to receive a concise daily digest of the latest news and analyst ratings for Zimmer Biomet and related companies with MarketBeat.com’s FREE daily email newsletter.